Hepatitis B Therapeutics Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This reports provides a data-driven overview of the current and future competitive landscape in Hepatitis B Therapeutics .
GlobalData epidemiologists estimate that there will be 21.91 million diagnosed prevalent cases of HBV in 2024, which is expected to increase to 22.43 million diagnosed prevalent cases by 2029.
The HBV treatment landscape has experienced successive waves of revolutionary change and is now dominated by antivirals and immunomodulatory therapies.
The HBV therapeutics pipeline holds 184 molecules, with one asset in the pre-registration stage, one asset in Phase III development, and 36 assets in Phase II development.
Over the past decade, 914 clinical trials have been conducted in HBV. The highest number of studies were initiated in 2018, with 118 trials, followed by 2020 with 107 trials.
Over the past decade, partnerships have been the most common type in North America and the APAC region. Meanwhile, licensing agreements led as the dominant deal in Europe, South and Central America, and Africa.
Scope
GlobalData’s Hepatitis B Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Hepatitis B Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Hepatitis B Therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Hepatitis B reports